What happened
Hanall Biopharma filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$26.9M (+10.7% year on year), operating profit of US$564K (from a loss a year earlier) and net income of US$185K (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$26.9M |
|---|---|
| Revenue vs a year earlier | +10.7% |
| Operating profit | US$564K |
| Net income | US$185K |
| Period | Q1 2026 (consolidated) |
| Filed | 2026-04-29, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260429800462 → open original filing |
Source: DART. Information only, not investment advice.